These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 15561812)

  • 21. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer.
    Small EJ; Smith MR; Seaman JJ; Petrone S; Kowalski MO
    J Clin Oncol; 2003 Dec; 21(23):4277-84. PubMed ID: 14581438
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness and cost of bisphosphonate therapy in tumor bone disease.
    Body JJ
    Cancer; 2003 Feb; 97(3 Suppl):859-65. PubMed ID: 12548587
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Imatinib mesylate and zoledronic acid in androgen-independent prostate cancer.
    Tiffany NM; Wersinger EM; Garzotto M; Beer TM
    Urology; 2004 May; 63(5):934-9. PubMed ID: 15134984
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rationale for zoledronic acid therapy in men with hormone-sensitive prostate cancer with or without bone metastasis.
    Saad F; McKiernan J; Eastham J
    Urol Oncol; 2006; 24(1):4-12. PubMed ID: 16414486
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial.
    Rosen LS; Gordon D; Tchekmedyian NS; Yanagihara R; Hirsh V; Krzakowski M; Pawlicki M; De Souza P; Zheng M; Urbanowitz G; Reitsma D; Seaman J
    Cancer; 2004 Jun; 100(12):2613-21. PubMed ID: 15197804
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers.
    Saad F; Lipton A
    BJU Int; 2005 Nov; 96(7):964-9. PubMed ID: 16225510
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group.
    Gnant MF; Mlineritsch B; Luschin-Ebengreuth G; Grampp S; Kaessmann H; Schmid M; Menzel C; Piswanger-Soelkner JC; Galid A; Mittlboeck M; Hausmaninger H; Jakesz R;
    J Clin Oncol; 2007 Mar; 25(7):820-8. PubMed ID: 17159195
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment.
    Marx RE; Sawatari Y; Fortin M; Broumand V
    J Oral Maxillofac Surg; 2005 Nov; 63(11):1567-75. PubMed ID: 16243172
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The clinical response on bone metastasis from breast and lung cancer during treatment with zoledronic acid is inversely correlated to skeletal related events (SRE).
    Facchini G; Caraglia M; Santini D; Nasti G; Ottaiano A; Striano S; Maiolino P; Ruberto M; Fiore F; Tonini G; Budillon A; Iaffaioli RV; Zeppetella GL
    J Exp Clin Cancer Res; 2007 Sep; 26(3):307-12. PubMed ID: 17987788
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of zoledronic acid on proteinase plasma levels in patients with bone metastases.
    Leto G; Badalamenti G; Arcara C; Crescimanno M; Flandina C; Tumminello FM; Incorvaia L; Gebbia N; Fulfaro F
    Anticancer Res; 2006; 26(1A):23-6. PubMed ID: 16475674
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical benefits and considerations of bisphosphonate treatment in metastatic bone disease.
    Saad F; Lipton A
    Semin Oncol; 2007 Dec; 34(6 Suppl 4):S17-23. PubMed ID: 18068486
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of zoledronic acid on renal function in patients with cancer: Clinical significance and development of a predictive model.
    McDermott RS; Kloth DD; Wang H; Hudes GR; Langer CJ
    J Support Oncol; 2006; 4(10):524-9. PubMed ID: 17136870
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bisphosphonates and metastatic breast carcinoma.
    Lipton A
    Cancer; 2003 Feb; 97(3 Suppl):848-53. PubMed ID: 12548585
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The risk of renal impairment in hormone-refractory prostate cancer patients with bone metastases treated with zoledronic acid.
    Oh WK; Proctor K; Nakabayashi M; Evan C; Tormey LK; Daskivich T; Antràs L; Smith M; Neary MP; Duh MS
    Cancer; 2007 Mar; 109(6):1090-6. PubMed ID: 17311345
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A prospective, multicenter, open-label trial of zoledronic acid in patients with hormone refractory prostate cancer.
    Hong SJ; Cho KS; Cho HY; Ahn H; Kim CS; Chung BH
    Yonsei Med J; 2007 Dec; 48(6):1001-8. PubMed ID: 18159593
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimal management of metastatic bone disease.
    Major P
    Eur J Oncol Nurs; 2007; 11 Suppl 2():S32-7. PubMed ID: 17804294
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Suppression of bone density loss and bone turnover in patients with hormone-sensitive prostate cancer and receiving zoledronic acid.
    Ryan CW; Huo D; Bylow K; Demers LM; Stadler WM; Henderson TO; Vogelzang NJ
    BJU Int; 2007 Jul; 100(1):70-5. PubMed ID: 17552955
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Breast cancer: bisphosphonate therapy for metastatic bone disease.
    Body JJ
    Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6258s-6263s. PubMed ID: 17062710
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy.
    Migliorati CA; Schubert MM; Peterson DE; Seneda LM
    Cancer; 2005 Jul; 104(1):83-93. PubMed ID: 15929121
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Zoledronic acid (Zometa): bisphosphonate for prostate cancer/bone metastases.
    Gaines KK
    Urol Nurs; 2002 Dec; 22(6):398-400. PubMed ID: 12593231
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.